Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges

Trends Cancer. 2017 Jun;3(6):391-406. doi: 10.1016/j.trecan.2017.04.008.

Abstract

In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term 'migrastatics' for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.

Keywords: contractility; invasion; metastasis; migrastatics; solid cancer; treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor
  • Cell Movement / drug effects*
  • Drug Discovery*
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Humans
  • Molecular Targeted Therapy
  • Neoplasm Metastasis / drug therapy*
  • Neoplasms / drug therapy
  • Neoplasms / etiology
  • Neoplasms / metabolism
  • Neoplasms / pathology*
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor